Self-assembling underwater adhesives
Compositions, methods, and kits are provided which involve novel fusion protein-based adhesives for use in medical and marine applications. In some aspects, the novel fusion proteins comprise an adhesive domain (e.g., derived from an adhesive protein of a marine organism) and an amyloid domain (e.g., derived from a bacterial amyloid protein). Also provided are copolymers and fibers of the fusion proteins.
1. A fusion protein comprising
a mussel foot protein (Mfp) that is Mfp3 (SEQ ID NO:1 or SEQ ID NO:3) or Mfp5 (SEQ ID NO:2 or SEQ ID NO:4), respectively, and
CsgA of SEQ ID NO:7 or fragments thereof.
2. The fusion protein of claim 1 , wherein the CsgA comprises one or more CsgA fragments selected from the group consisting of SEQ ID NOs: 13-18.
3. The fusion protein of claim 1 , wherein the Mfp is Mfp3.
4. The fusion protein of claim 1 , wherein the Mfp is Mfp5.
5. The fusion protein of claim 1 , wherein the Mfp3 or Mfp5 is fused to the C-terminus of the CsgA, the Mfp3 or Mfp5 is fused to the N-terminus of the CsgA, or the Mfp3 or Mfp5 is fused within the CsgA.
6. The fusion protein of claim 1 comprising SEQ ID NO:9 (Mfp5-CsgA) or SEQ ID NO:8 (CsgA-Mfp3).
7. The fusion protein of claim 1 , further comprising one or more polypeptides selected from fibronectin, histatin, and epidermal growth factor (EGF).
8. A fiber comprising at least one type of fusion protein of claim 1 .
9. The fiber of claim 8 , wherein the fiber comprises CsgA-Mfp3 and Mfp5-CsgA fusion proteins.
10. The fiber of claim 9 , wherein the CsgA-Mfp3 and Mfp5-CsgA are present in a molar ratio of about 1:20 to 20:1 CsgA-Mfp3:Mfp5-CsgA, a molar ratio of about 1:15 to 15:1 CsgA-Mfp3:Mfp5-CsgA, a molar ratio of about 1:3 to 3:1 CsgA-Mfp3:Mfp5-CsgA, or a molar ratio of about 1:1 CsgA-Mfp3:Mfp5-CsgA.
11. The fiber of claim 8 , wherein the fiber comprises a CsgA-Mfp3 fusion protein or a Mfp5-CsgA fusion protein.
12. An composition comprising one or more fusion proteins of claim 1 .
13. A composition comprising one or more fusion proteins of claim 1 , and a pharmaceutically acceptable carrier.
14. The composition of claim 13 , further comprising an agent that promotes wound healing, wherein the agent that promotes wound healing is a growth factor or antibiotic.